XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
  Asthma
  COPD
  Cystic Fibrosis
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Respiratory Medicine Channel
subscribe to Respiratory Medicine newsletter

Latest Research : Respiratory Medicine

   DISCUSS   |   EMAIL   |   PRINT
Home-Away®Oxygen System Approved by FDA for Easy Oxygen at Home
Apr 25, 2005, 08:15, Reviewed by: Dr.

“The revolutionary Home-Away System will enable patients on LTOT to remain mobile and maintain their quality of life. Additionally, it is exciting news for home healthcare providers because it eliminates costly and time-consuming deliveries while offering patients full mobility with the preferred form of ambulatory oxygen."

 
In-X Corporation, of Denver, CO, developer and manufacturer of home oxygen liquefaction systems received FDA Clearance today for the Home-Away® System. The Home-Away System enables patients with Long Term Oxygen Therapy (LTOT) needs to produce liquid oxygen in their home, thus eliminating the need for expensive deliveries.

“The revolutionary Home-Away System will enable patients on LTOT to remain mobile and maintain their quality of life. Additionally, it is exciting news for home healthcare providers because it eliminates costly and time-consuming deliveries while offering patients full mobility with the preferred form of ambulatory oxygen”, said Doug Powell, president of In-X Corporation.

The Home-Away System works in conjunction with any In-X approved oxygen concentrator to create liquid oxygen within the patient’s home. The system directs a portion of the oxygen flow from the concentrator directing it to a cryogenic cooling device, where it is condensed into liquid and stored within the system until it is ready to be transfilled into a portable liquid unit. The remaining oxygen gas produced by the concentrator is available for patient use at a flow of up to 3 lpm. The portable liquid unit is worn around the patient’s waist (similar to a fanny pack); weighs just 4.2 lbs when full and provides a typical patient with 6-8 hours of mobility per fill. The Home-Away System produces enough liquid oxygen for a patient to fill the portable liquid unit 3 times per day.

In-X anticipates having the Home-Away System ready for sale to home healthcare providers in the last quarter of 2005 with product delivery the first quarter of 2006.
 

- U.S. Food and Drug Administration (FDA)
 

FDA

 
Subscribe to Respiratory Medicine Newsletter
E-mail Address:

 

For more information on the new Home-Away System, call Doug Powell, President, In-X Corporation at (303) 574-3115 ext. 103.

Company Background – In-X Corporation
In-X Corporation is a developer of advanced respiratory care products and is the exclusive source for the Home-Away System. Founded in 1997, In-X Corporation is a medical technology company based in Denver, CO.


Related Respiratory Medicine News

Acute lung injury is prevented by FoxM1 protein
Six-minute walk test predicts mortality rates in patients with pulmonary fibrosis
A dog in home may worsen asthma in children
Cystic fibrosis-related diabetes is due to functional abnormalities in beta cells
COPD patients using beta-agonist inhalers are at risk
Beta-agonists linked with increased number of respiratory deaths -study shows
Beta-agonists more than double death rate in COPD patients
No evidence for inhaled corticosteroids efficacy in cystic fibrosis
Lung function test underused in patients with COPD
Wrinkles clue to risk of progressive lung disease (COPD)


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us